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treating such patients. Sixty-three autologous HSCT were per-
formed from August, 1994 to September, 2003; 80% of them were
after 1999. Thirty-four patients were male (54%). The median age
was 7 years (1 to 23). The underlying diagnoses were neuroblas-
toma (24), Wilms’ tumor (10), Ewing’s Sarcoma (9), medulloblas-
toma/ central nervous system primitive neuroectodermal tumor
(8), germ cell tumors (6), rhabdomyosarcoma (5) and desmoplasic
small round cell tumor (1). Twenty-one patients with neuroblas-
toma, two with medulloblastoma (under 3 years of age) and one
with metastatic rhabdomyosarcoma were in ﬁrst remission. The
others were in second or third remission or had refractory disease
(39). Melphalan, etoposide and carboplatin was the conditioning
regimen used in 68% of the patients. The peripheral blood was the
source of stem cells in 72% of them. The overall and disease free
survival at four years were 39  8% and 33  7%, respectively.
The median survival was 22  6 months. The overall survival,
according to diagnosis, was 53  11% for neuroblastoma, 58 
16% for Wilms’ tumor, 33 16% for Ewing’s sarcoma, 58 19%
for medulloblastoma, 50  29% for germ cell tumors and 20 
18% for rhabdomyosarcoma. Relapse was the main cause of
death (21/63-32%). Nine patients (14%) died due to trans-
plant-related toxicity or infections. In conclusion, HSCT is
feasible but carries a high transplant-related mortality. A Brazilian
HSCT registry is being organized. National trials are warranted
for better indication and evaluation of the role of stem cell trans-
plantation in the treatment of high-risk or relapsed pediatric solid
tumors.
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AUTOLOGOUS STEM CELL TRANSPLANTATION (SCT) IN PEDIATRIC
PATIENTS WITH ADVANCED HODGKIN’S LYMPHOMA (HL): THE ROLE
OF INTERFERON-ALPHA POST-TRANSPLANT
Petropoulos, D.1, Worth, L.L.1, Mullen, C.A.1, Lockhart, S.2, Ramirez,
I.1, Chan, K.W.1 1. MD Anderson Cancer Center, Houston, TX; 2.
Children’s Hospital of Austin, Austin, TX
Interferon alpha (IFN	) has known anti-proliferative and immu-
nomodulating effects and might enhance immunity for better con-
trol of any residual HL after SCT. Between May 1994 and August
2003 a total of 12 pediatric (8 males) patients with HL (8 NS, 2 LP,
1MC, 1 NSALCL) underwent autologous SCT in our center.
Their median age was 16 (range 11-20) years. The median interval
between diagnosis and transplant was 16 months (range 6mos-9 y).
All patients had received a median of 3 prior treatments (range 2-4)
and all but two additional involved-ﬁeld radiotherapy. Disease
status at the time of SCT was: PD (4 patients), SD (2), PR (4), and
CR(2). The conditioning regimens were BEAM (n 6), CBV (n
3), or other(n  3) The source of SC was autoBM in 2 cases and
autoPBSC in 10. All patients achieved ANC and PLT engraftment
after a median time of 10 (9-16) and 12 (11-31) days respectively.
Nine patients received IFNa immunotherapy when the ANC and
the platelet count exceeded 1,500 and 50,000 respectively. Three
did not, two due to rapidly progressive disease. Interferon-	 ad-
ministration was initiated at a dose of 0.5 million Units/m2 tiw
(Klingerman et al, Blood 1991,78: 3306) at a median of 49 days
post-transplant (range 33-127). Patients received IFN	 for 1 to 24
months (median 12 months post-transplant). Observed toxicity was
hematologic and constitutional, with escalation of dose and/or
frequency as permitted by toxicity. The median tolerated weekly
dose was 3.5(range 1.5-6.5) mU/m2. With a median follow-up of
41(range 2-113) months, nine patients are alive and well (two less
than a year post SCT). Of the 10 patients who received IFN	, nine
are alive with no evidence of disease. Three patients died: two from
rapidly progressive HL (did not receive IFN	) and one from
relapse following allogeneic BMT. One patient, who relapsed after
transplant, was treated with IFN	 and chemotherapy and remains
in remission 5 years later. In conclusion, IFN-	 administration to
pediatric patients following SCT for advanced HL is safe and may
confer survival advantage.
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STEM CELL TRANSPLANTATION (SCT) FOR PATIENTS(PTS) WITH GE-
NETIC DISEASES: A CALL FOR PHYSICIANS FROM DEVELOPING COUN-
TRIES TO DISCUSS ABOUT STRATEGIES TO IMPROVE DIAGNOSIS AND
EARLY REFERRAL TO BMT CENTERS
Bonﬁm, C.M.S., Bitencourt, M.A., Setubal, D.C., Moreira, V.A.,
Lorenzato, C., Ruiz, J., Zanis Neto, J., de Medeiros, C.R., Pasquini, R.
BMT Center-Federal University of Parana, Curitiba, PR, Brazil
Background: Brazil is a huge Latin-American country with
many social and economic disparities and more than 3 million live
births every year. SCT for pts with genetic diseases (GD) has a
speciﬁc timing because engraftment of donor cells does not always
correlate with improved quality of life or survival. Material and
Methods: Between 10/79 and 09/03 more than 1400 SCT were
performed in our BMT Unit but only 51 pts had GD. Median age:
3yr (range: 0,1 to 22). Gender: F11/M40; Diagnoses: Dyskeratosis
Congenita (DC): 5pts;Diamond-Blackfan Anemia (DBA): 5pts;
Congenital Dyserythropoietic Anemia (DBA): 1pt; Amegakaryo-
cytic Purpura (AmegaP): 1pt; Hemoglobinopathies: 4pts; Kost-
mann Syndrome: 1pt; Wiskott-Aldrich syndrome (WAS): 7pts;
Severe Combined Immunodeﬁciency (SCID): 7pts; Histiocytoses:
1pt; Gaucher disease: 1pt; Mucopolysaccharidosis: 6pts (MPS-I:
3pts, MPS-III: 1pt, MPS-VI: 2pts); Adrenoleukodystrophy (CO-
CALD): 3pts; Globoid Cell Leukodystrophy (GLD-Krabbe): 1pt;
Osteopetrosis (OP): 8pts. Bone marrow (BM) was the stem cell
source for 30 HLA-identical siblings, 3 other related and 1 hap-
loidentical (mother). 17pts received an unrelated transplant (11CB,
6BM). Conditioning regimen: Chemotherapy only: 41pts, Chemo-
therapy TBI: 7pts. No conditioning regimen: 3pts. GVHD pro-
phylaxis: Csa was given to 47pts. Results: 48pts were evaluable for
engraftment and 10pts had primary graft failure (osteopetrosis:
6pts). Thirty-three pts (DBA: 3pts; Gaucher: 1pt; MPS: 3pts; OP:
2pts, DC: 5pts, Hemoglobinopathies: 4pts, SCID: 6pts, WAS:
5pts; COCALD: 2pts; AmegaP: 1pt Histiocytoses: 1pt) are alive 6
to 5688 days post-BMT (Median: 1377days). Four pts are alive
with an autologous recovery (OP: 2pts, Hemoglobinopathies:
2pts). All pts with storage disease that are alive improved or
stabilized their neurological function, except for 1pt with MPS-III.
Eighteen pts died (14pts before day100). GVHD or graft-failure
associated with infections was responsible for most deaths. Con-
clusion: Medical education to improve early diagnosis and referral
to specialized centers is the key to success in GD. This has to be
done together with the commitment from the health system in
each country to guarantee that all pts will be able to receive
adequate treatment despite their economic or social background. It
is urgent that developing countries work together with interna-
tional centers to improve diagnosis, data collection and speciﬁc
treatments in these rare diseases.
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UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR FA-
MILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS
Archambault, B.L., Driscoll, T.A., Stafford, L.A., Szabolcs, P., Kurtzberg,
J., Martin, P.L. Duke University Medical Center, Durham, NC
Background: Patients with Familial Erythrophagocytic Lym-
phohistiocytosis (FEL) or Hemophagocytic Lymphohistiocytosis
(HLH) die of progressive disease early in life. Allogeneic stem cell
transplantation may be curative. However, many children lack a
suitably matched living related or unrelated donor. This study
investigated the feasibility of substituting partially HLA-mis-
matched, banked unrelated-donor umbilical cord blood (UCB) as
an alternative source of hematopoietic stem cells for transplanta-
tion in children with FEL lacking traditional HLA matched stem
cell donors. Methods: Five infants with FEL, with a median age of
0.58 years, (range 0.33-0.98) received myeloablative doses of busul-
fan, cyclophosphamide and ATG followed by unrelated UCB
transplantation between 11/98 and 2/02. Patients were evaluated
for donor cell engraftment, toxicity and effects of this therapy on
the natural history of the disease. Patients did not receive any post
transplant intrathecal therapy. No radiation therapy was adminis-
tered at any time during therapy. Results: UCB donors mis-
matched at 1-2 HLA markers delivering a median cell dose of
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